plerixafor has been researched along with Cryptogenic Fibrosing Alveolitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Guo, X; Lian, H; Rosas, I; Wang, L; Wang, N; Xia, C; Xu, K; Yang, J; Yu, G; Zhao, W | 1 |
| Chen, G; Ding, L; Li, Z; Oupicky, D; Sun, M; Wang, Y | 1 |
| Coelho, AL; Espindola, MS; Habiel, DM; Hogaboam, CM | 1 |
3 other study(ies) available for plerixafor and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration.
Topics: Animals; Bleomycin; Bosentan; Endothelial Cells; Epithelial-Mesenchymal Transition; Humans; Idiopathic Pulmonary Fibrosis; Lung; Matrix Metalloproteinases, Secreted; Mice; Monocytes | 2023 |
Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes.
Topics: Acute Lung Injury; Animals; Benzylamines; Cyclams; Disease Models, Animal; Emulsions; Heterocyclic Compounds; Idiopathic Pulmonary Fibrosis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polymers; Receptors, CXCR4; RNA, Small Interfering; Survival Rate; Tissue Distribution | 2019 |
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.
Topics: Animals; Antibodies, Neutralizing; Benzylamines; Cyclams; Disease Models, Animal; Fibroblasts; Heterocyclic Compounds; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-13; Lung; Mice, SCID; Phenotype; Receptors, CXCR4; Receptors, Interleukin-4 | 2018 |